Pharma & Biotech Economics
Biosimilars: Cheaper Copies of Biologic Drugs
Why biologic medicines made from living cells are costly, how biosimilars bring competition, and how Indian firms like Biocon entered the market.
Many modern medicines, such as insulin, cancer antibodies and treatments for arthritis, are biologics: large, complex molecules made using living cells.
Why biologics are expensive
- Complex manufacturing in controlled facilities.
- Hard to copy exactly.
- Often protected by patents and long exclusivity periods.
Some biologics cost tens of thousands of dollars a year per patient.
What biosimilars are
A biosimilar is a close copy of a biologic after its patents expire. Unlike simple generics, which are chemically identical, biosimilars are “highly similar” with no meaningful differences in safety or effect. Making them requires expensive development and testing, but far less than a new drug.
The economics
- Biosimilars usually sell at discounts of perhaps 15 to 50 percent or more, less than typical generic discounts, because development is costlier.
- Competition can push down prices of the original biologic too.
- Adoption depends on doctors’ trust and regulations.
India’s players
Biocon, founded by Kiran Mazumdar-Shaw in Bengaluru in 1978, became one of the world’s leading biosimilar makers, including biosimilar insulins and cancer drugs sold in the US and Europe. Other Indian firms such as Dr. Reddy’s and Intas also make biosimilars.
Why it matters
Biologics are a growing share of drug spending. Biosimilars can make treatments for diabetes, cancer and autoimmune diseases far more affordable.
When the patent on a cancer antibody expires, several firms launch biosimilars. Prices fall, and hospitals in lower-income countries can treat many more patients with the same budget.
Biosimilars are highly similar but not identical, and cost much more to develop than chemical generics.
- Biologics are complex drugs made from living cells and are often very expensive.
- Biosimilars are close copies launched after patents expire.
- They offer meaningful but smaller discounts than generics.
- Biocon and other Indian firms are major biosimilar makers.
No recording for this one yet - EconReader can read it aloud for you.